Altogether, GPR40-mediated β-cell toxicity is specific for some AgoPAM agonists but not partial agonists, which has been proven in clinical trials of TAK-875 and no β-cell related adverse effects were reported in chronically treated T2D patients (Burant et al., 2012). Here, FFAR1 is linked to type 2 diabetes mellitus.